GNC-New York Agreement Spurs States’ Call To Tighten Supplement Industry Scrutiny
This article was originally published in The Tan Sheet
Executive Summary
The agreement, which follows a recall based on the New York AG’s testing of herbal supplements purchased from GNC, could spur other states to look at requirements that exceed FDA’s supplement GMPs. NY AG Schneiderman says his “investigation raised questions regarding the sufficiency” of FDA regulations “in relation to state consumer protection laws.”
You may also be interested in...
GNC Supply Chain Reform Pays Dividends In DoJ Settlement From DMAA Investigation
DoJ announces a "non-prosecution agreement" that requires GNC to pay $2.25m and to cooperate in dietary supplement market investigations conducted by FDA and other federal agencies, including the current litigation against USPlabs.
New York AG Plies Third Pact Pushing DNA Testing On Supplement Firms
NBTY notes that FDA regulations allow firms flexibility in test methodologies for ingredient identity and other testing required under the supplement GMP final rule, and industry stakeholders say compliance with the GMPs is the standard, not a state agency's preferences.
Jurors' Answers In FTC's Prevagen Complaint Might Burst A Memory Bubble For Health Claims
“No” answers in New York federal court on whether all but two of Prevagen claims were “materially misleading” could put a fork in the road of a long dispute between FTC and supplement product manufacturers and marketers.